International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: 10.5281/zenodo.13374368
Original Research Article
A Clinical Study on the Feasibility and Safety of Eustachian Tube Dilation Using a Standard Endovascular Balloon
Published
Dec. 19, 2024
Abstract

Background: Balloon dilation of the Eustachian tube traditionally employs specialized devices, limiting accessibility and increasing costs. This study evaluated the feasibility and safety of using standard endovascular balloons for this procedure.Methods: A prospective, single-center study enrolled 75 adults with chronic Eustachian tube dysfunction. Standard endovascular balloons were used for dilation under general anesthesia. Primary outcomes included technical success and safety. Secondary outcomes included changes in ETDQ-7 scores, tympanometric parameters, and patient satisfaction at 6 weeks post-procedure.Results: Technical success was achieved in 96% of cases. ETDQ-7 scores improved significantly from 4.8 ± 0.9 to 2.1 ± 0.6 (p<0.001) at 6 weeks. The complication rate was 34.7%, predominantly minor and self-limiting, with 92.3% resolution within 6 weeks. Type A tympanograms increased from 0% to 77.3% at 6 weeks (p<0.001). Mean air-bone gap improved from 28.5 ± 8.4 dB to 12.8 ± 5.4 dB (p<0.001). Younger age (≤45 years, OR=1.8, p=0.023) and shorter symptom duration (≤12 months, OR=2.4, p=0.002) predicted better outcomes. Patient satisfaction reached 92% with mean recovery time of 3.2 days.Conclusion: Eustachian tube balloon dilation using standard endovascular balloons demonstrates favorable safety and efficacy profiles, offering a potentially cost-effective alternative to specialized devices.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
2807 Views
143 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved